Cost-effectiveness of Disitamab Vedotin Plus Toripalimab in HER2-Expressing Urothelial Cancer
The RC48-C016 trial conducted in China demonstrated that disitamab vedotin combined with toripalimab (DV+Torip) significantly improved overall survival and progression-free survival compared to traditional chemotherapy in patients with HER2-expressing advanced urothelial cancer.
Phase III
Oncology / HER2-Expressing Advanced Urothelial Cancer
Status
Positive
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Strategic implication
The cost-effectiveness of DV+Torip may support its adoption as a first-line treatment, influencing pricing strategies and market positioning against chemotherapy.
Why it matters
The results from the RC48-C016 trial introduce a pivotal shift in the treatment landscape for HER2-expressing advanced urothelial cancer.
Recommended action
Humanexa recommends Monitor: Humanexa advises monitoring developments related to the RC48-C016 trial results and subsequent market access discussions. Given the potential for disitamab vedotin plus toripalimab to disrupt existing treatment paradigms, staying informed on pricing negotiations and changes in treatment guidelines will be critical for strategic positioning and competitive analysis.
Analysis
Monitor updates on the RC48-C016 trial results, pricing negotiations, and market access discussions in China.
Related companies & assets
Assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.